(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…
Source link : https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/119134
Author :
Publish date : 2025-12-22 17:56:00
Copyright for syndicated content belongs to the linked Source.
